Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant bevacizumab + carboplatin + paclitaxel in early and locally advanced triple-negative breast cancer
2010-022077-33Phase 2Completed
- Sponsor
- AOU Policlinico di Modena
- Start
- Dec 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in triple-negative breast cancer (TNBC), sponsored by AOU Policlinico di Modena. Primary endpoint: Pathological complete response (pCR). Started Dec 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2010-022077-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022077-33.